Intellia Therapeutics Makes Strides in Gene Editing with FDA Submission for Lonvoguran Ziclumeran

On April 27, 2026, Intellia Therapeutics, Inc. (Nasdaq: NTLA), a pioneering biopharmaceutical firm specializing in gene editing, announced a significant advancement in its clinical pipeline. The company has initiated a rolling submission of a biologics license application (BLA) to the U.S. Food and Drug Administration (FDA) for lonvoguran ziclumeran (lonvo-z), a one-time treatment for hereditary angioedema (HAE). This groundbreaking therapy utilizes in vivo CRISPR gene editing technology, aiming to provide a permanent solution for patients suffering from this rare genetic condition.

Lonvo-z, previously designated NTLA-2002, is designed to permanently inactivate the kallikrein B1 (KLKB1) gene, which is implicated in the pathogenesis of HAE. By targeting this gene, lonvo-z seeks to lower the levels of kallikrein and bradykinin, thereby preventing the debilitating swelling attacks that characterize HAE.

Intellia's recent Phase 3 HAELO clinical trial yielded positive topline data, indicating that a single dose of lonvo-z could free most patients from HAE attacks and the need for ongoing therapy during the six-month observation period. This outcome not only reinforces the potential efficacy of lonvo-z but also positions it as a possible game-changer in the treatment landscape for HAE.

The FDA has granted lonvo-z the Regenerative Medicine Advanced Therapy (RMAT) designation, which facilitates a rolling submission process. This allows Intellia to submit portions of the BLA incrementally, expediting the review process by providing the FDA with ongoing insights into the clinical data.

In conjunction with the RMAT designation, Intellia has also engaged with the FDA through the Chemistry, Manufacturing, and Controls (CMC) Development and Readiness Pilot program. This initiative enhances communication with regulatory staff, aimed at addressing queries and ensuring that the development of lonvo-z remains on track.

Intellia anticipates completing the BLA submission in the latter half of 2026. Should the FDA accept the filing, the agency may grant priority review status, expediting the evaluation process. If approved, Intellia plans to commercially launch lonvo-z in the first half of 2027.

Hereditary angioedema is a rare genetic disorder that affects approximately one in 50,000 individuals, leading to severe, unpredictable swelling in various body organs and tissues. Current treatment options often require lifelong therapies, which can involve frequent intravenous or subcutaneous administration, leaving many patients burdened by the need for continuous care and the risk of breakthrough attacks.

By offering a one-time treatment option, lonvo-z has the potential to significantly improve the quality of life for HAE patients, allowing them to live free from the constant worry of swelling attacks and the need for ongoing therapy.

John Leonard, M.D., President and CEO of Intellia, expressed optimism about the potential of lonvo-z, stating, “If approved, lonvo-z will become the world’s first *in vivo* CRISPR-based gene editing therapy. The promising results from HAELO reinforce our conviction that lonvo-z could revolutionize how HAE is treated for many patients.”

Intellia Therapeutics is on the cusp of a major breakthrough in the treatment of hereditary angioedema with its gene editing therapy lonvo-z. With the initiation of its rolling BLA submission and the promising clinical trial results, the company is poised to significantly alter the treatment landscape for HAE patients. As it continues to engage with regulatory authorities, the biopharmaceutical community and patients alike await the outcome with hopeful anticipation.